Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 54Other hematologic neoplasm 26Plasma cell 1Myeloid 1Head & Neck 1Genitourinary 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Anemia 1

Interventions

Cyclophosphamide 11fludarabine phosphate 9Whole-Body Irradiation 8Mycophenolic Acid 7Busulfan 6fludarabine 5Tacrolimus 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Rituximab 4Biopsy 4Azacitidine 4venetoclax 3apixaban 3Cyclosporine 3thymoglobulin 2decitabine and cedazuridine drug combination 2Vorinostat 2Vancomycin 2Tretinoin 2Specimen Handling 2Sirolimus 2Methotrexate 2Lenalidomide 2Injections 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Decitabine 2Cytarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ibrutinib × Classical hematology × 90 days × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡